Skip to main content
. Author manuscript; available in PMC: 2008 Sep 1.
Published in final edited form as: Bioorg Med Chem. 2007 Jun 10;15(17):5694–5709. doi: 10.1016/j.bmc.2007.06.015

Figure 7.

Figure 7

(A) Comparison of in vivo potency of PMB and EVK-203 in a D-galactosamine-primed murine model of lethal endotoxic shock. Dose-dependent increase in survival in mice challenged with a supralethal (200 ng/animal; 2X LD100) dose of LPS. The difference in dose-dependent survival rates between animals receiving PMB and EVK-203 was statistically significant (p<0.005; Fisher one-tailed exact probability). (B) Time-course (pharmacodynamics) of protection conferred by 8 mg/kg of EVK-203 administered at various times prior to, and following supralethal LPS challenge in a D-galactosamine-primed murine model of lethal endotoxic shock. LPS (200 ng/animal; 2X LD100) was administered at time = 0 h.